News

Ideas That Generate Results

According to a new research report by RNCOS entitled, “Global Antibody Drug Conjugate Market Outlook 2018”, an ADC is designed by site-specific conjugation of cytotoxic agent (drugs) to a monoclonal antibody. Cytotoxic agents are drugs which are used in the treatment of cancer. By combining the functionalities of a drug and antibody, pharmacokinetic parameters and therapeutic action of antibody drug conjugate are improved. Industry leaders are using several kinds of potent agents such as Monomethyl auristatin E, maytansine derivatives and Pyrrolobenzodiazepine among others.
 
By observing at the market developments, RNCOS has analyzed that more than 50% of the ADCs are using Monomethyl auristatin (MMAE) to construct ADCs. Examples of such ADCs include Anti-PSMA-ADC for prostate cancer, RG7596 for hematological cancer, RG7596 to target platinum-resistant ovarian cancer etc. Monomethyl auristatin E (MMAE) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. It is an antimitotic agent which inhibits cell division by blocking the polymerization of tubulin. Experimental evidences have shown that MMAE shows up to 200 times more potency than other drugs. Also MMAE has high penetration when linked to mAb as contrast to other drugs. Rest of the drugs like Maytansine derivatives and PBD constitute 30% and 10% of the marketed ADCs. With greater number of usefulness MMAE-mAb constructs to treat cancers, ADCs demand will show a spike in future.
 
This report is spread over 65 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Antibody Drug Conjugate market. The report analyzes the market for Adcetris and Kadcyla in detail. Market potential for these drugs has been estimated keeping in mind the fact that these drugs are being tested in clinical trials for various indications apart from the ones for which they are approved. The report also provides an insight into the key ADCs that are currently in pipeline. A brief analysis on the types of ADCs is being done on the basis of types of drug used, clinical phases and cancers targeted. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place over ADC have been provided. At the end, major players of ADC market have been discussed. A brief business overview of every player has been provided alongwith their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM667.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm